Analysts have set 12-month price targets for BioNTech, revealing an average target of $132.24, a high estimate of $171.00, ...

Analysis of Pfizer's financial performance, acquisitions, and future prospects, highlighting key challenges and opportunities ...

Yes, you can get your flu and COVID-19 shots at the same time. Don't call them boosters -- they're not just another dose of ...

More than a few companies that did well in the past are out of favor with investors. And that could spell opportunity.

Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

Pfizer has a pill it's developing called danuglipron, which is in early-stage trials but has demonstrated that it's ...

The company’s updated guidance for revenue includes approximately $10.5B in anticipated revenues for Comirnaty and Paxlovid, approximately $5B and $5.5B, respectively. Including the contribution ...

One stock yields 6% today. Another has grown its dividend by 460% over the past decade. Both are blue chip bargains to buy ...

According to The People’s Vaccine Alliance, Comirnaty costs an estimated $1.18 per dose to produce. For over two years now, the US government has been running its public vaccination campaign ...

Pfizer also provides medicines and vaccines in various therapeutic areas, such as: Pneumococcal disease, meningococcal ...

Arcturus Therapeutics (ARCT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...